Tesamorelin vs IGF-1 LR3.

Tesamorelin is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH/GRF 1-44), stabilized by a trans-3-hexenoic acid group attached to its N-terminus. It is one of the few research peptides in its class that holds full FDA approval, marketed as Egrifta (and the reformulated Egrifta SV / Egrifta WR) by Theratechnologies for a narrow, specific indication. Originally designated TH9507, it is a secretagogue rather than a hormone itself.

IGF-1 LR3 (Long R3 IGF-1) is a synthetic, recombinant analog of human insulin-like growth factor-1. It is an 83-amino-acid polypeptide built from the 70-residue native IGF-1 sequence with two structural changes: a glutamate-to-arginine substitution at position 3 and a 13-residue N-terminal extension peptide. It is produced and sold primarily as a research reagent and as a cell-culture supplement (marketed under names such as LONG R3 IGF-I), not as a licensed human medicine.

Tesamorelin binds the GHRH receptor on the anterior pituitary, stimulating the synthesis and pulsatile release of the body's own growth hormone (GH), which in turn raises hepatic and circulating insulin-like growth factor-1 (IGF-1). Because it works upstream by amplifying endogenous GH secretion, it largely preserves physiological feedback and pulsatility, unlike direct exogenous GH administration. The N-terminal hexenoyl modification confers resistance to degradation (including by dipeptidyl peptidase-IV) and extends its half-life relative to native GHRH. The downstream rise in GH/IGF-1 drives lipolysis, with a notable effect on visceral (intra-abdominal) adipose tissue.

Like native IGF-1, LR3 binds and activates the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase that signals through the PI3K/Akt/mTOR and Ras/MAPK pathways to drive protein synthesis, cell proliferation, and survival. Its distinguishing feature is engineered: the position-3 arginine substitution plus the N-terminal extension dramatically lower its affinity for the six IGF-binding proteins (IGFBPs) that normally sequester circulating IGF-1. Because little of the analog is bound and held by IGFBPs, a much larger fraction remains free to engage IGF-1R, and in animal models its circulating half-life is substantially longer than that of native IGF-1. This same "escape from IGFBP regulation" is why it is favored in mammalian cell culture, where it resists sequestration by cell-secreted binding proteins.

Human evidence is unusually strong for one specific population: HIV patients with lipodystrophy. Two pivotal phase 3 randomized, placebo-controlled trials and their pooled analysis (Falutz et al., JAIDS 2010 and J Clin Endocrinol Metab 2010) showed roughly a 15-18% reduction in visceral adipose tissue over 26 weeks, with regain after discontinuation, supporting the FDA approval. Stanley et al. (JAMA 2014; PMID 25038357) and a randomized NAFLD trial (Stanley et al., Lancet HIV 2019; PMID 31611038) further demonstrated reductions in liver fat and a lower rate of fibrosis progression in HIV-associated fatty liver disease. Crucially, nearly all rigorous human data come from HIV-positive cohorts; use for general anti-aging, body recomposition, or NAFLD in HIV-negative people is extrapolation and has not been established in large controlled trials. Subcutaneous fat and total weight are largely unaffected, and effects reverse when treatment stops.

Direct evidence for LR3 is overwhelmingly preclinical and in-vitro, not clinical. In a guinea pig study (Conlon et al., J Endocrinol 1995, PMID 7561636), Long R3 IGF-I infusion stimulated organ growth while paradoxically lowering plasma IGF-I, IGF-II, and IGFBP concentrations, illustrating its altered binding-protein behavior in vivo. A mouse study (J Endocrinol 2008, PMID 18577570) reported that long-R3-IGF-I altered mammary signaling and gene expression during prolonged lactation. Analytical work (J Chromatogr B 2003, PMID 12880859) characterized the molecule for bioanalytical detection. There are no controlled human trials demonstrating safety or performance/physique benefits for IGF-1 LR3 specifically; clinical inferences are extrapolated from native IGF-1 (mecasermin) and from receptor pharmacology, which is a meaningful gap because LR3's reduced IGFBP binding changes its tissue exposure relative to the natural hormone.

The most consistent documented concerns are glucose-related: because it raises GH/IGF-1, tesamorelin can worsen insulin sensitivity and glucose tolerance, and IGF-1 levels are monitored in clinical practice. Common adverse effects in trials included injection-site reactions, arthralgia, myalgia, peripheral edema, and paresthesia; hypersensitivity reactions have occurred. It is contraindicated in pregnancy and in people with active malignancy, since elevated IGF-1 is a theoretical tumor-growth concern, and in those with disrupted hypothalamic-pituitary axis (e.g., pituitary tumor/surgery, head irradiation). The NIH LiverTox database assigns it a low likelihood of causing clinically apparent liver injury. Long-term safety beyond the trial windows, and safety in non-HIV populations, remains poorly characterized.

No human safety dataset exists for IGF-1 LR3 itself; the closest human reference is the FDA-approved native IGF-1 drug mecasermin (Increlex), whose label documents hypoglycemia (including severe, seizure-associated events from its insulin-like action), intracranial hypertension with papilledema, and lymphoid (tonsillar/adenoidal) tissue hypertrophy. Because IGF-1R signaling is mitogenic and anti-apoptotic, a theoretical concern across IGF-1 agonists is the promotion of growth in existing neoplastic tissue, though this has not been quantified for LR3 in humans. LR3's much longer free-ligand exposure could plausibly amplify these effects relative to native IGF-1, but this is unverified. Research-grade material also carries purity, sterility, and mislabeling risks that are not controlled to pharmaceutical standards.

FDA-approved (2010, as Egrifta; reformulated as Egrifta SV in 2019 and the F8 formulation Egrifta WR in 2023) solely to reduce excess visceral abdominal fat in HIV-infected adults with lipodystrophy. All other uses are off-label, and it is a prescription drug, not a dietary supplement.

IGF-1 LR3 is not approved by the FDA or any major regulator for human use; it is sold for laboratory research and cell-culture manufacturing only. The only FDA-approved IGF-1 product is mecasermin (Increlex), recombinant native IGF-1 indicated for severe primary IGF-1 deficiency, which is a different molecule. IGF-1 and its analogues are prohibited in sport at all times under WADA Prohibited List section S2.